NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

Great stuff! I think he is referring to the US market only, however. An interesting point made in another article went:

Rindopepimut targets a certain expression from the cancer, called EGFRvIII-positive, an expression that is estimated to be found in 30% of patients. Initial analysis pegs peak sales at $300 million, using current glioblastoma drugs as a guide.

Of course, DCVax would be ITT the entire GBM pop, and so conservative figures, using the above estimates, would be $1B in peak sales for DCVax-L. I think it would be even higher, but good start, and various sources are confirming this.